| | Variables | Yes (20, 25.6%) | No (58, 74.4%) | values |
| | Age at onset, Y, median [IQR] | 30 [20-55] | 25 [19-32] | 0.069 | | Sex: male, (%) | 9 (47.4%) | 29 (50.0%) | 0.842 | | Antibody positive, (%) | 8 (40.0%) | 17 (29.3%) | 0.377 | | Onset with seizures, (%) | 14 (70.0%) | 46 (79.3%) | 0.394 | | Status epilepticus, (%) | 1 (5.0%) | 4 (6.9%) | 0.765 | | Seizure type at onset | | | | | Generalized, (%) | 2 (10.0%) | 9 (15.5%) | 0.541 | | Focal motor, (%) | 8 (40.0%) | 24 (41.4%) | 0.914 | | Focal nonmotor, (%) | 5 (25.0%) | 3 (5.3%) | 0.012 | | Focal to bilateral, (%) | 14 (70.0%) | 40 (69.0%) | 0.931 | | Multiple seizure type, (%) | 8 (40.0%) | 18 (31.0%) | 0.463 | | FBDS, (%) | 0 | 1 (1.7%) | 0.555 | | Seizure frequency at onset | | | | | Daily, (%) | 11 (55.0%) | 32 (55.2%) | 0.989 | | Weekly, (%) | 7 (35.0%) | 12 (20.7%) | 0.199 | | Monthly, (%) | 2 (10.0%) | 14 (24.1%) | 0.177 | | Drug resistance to ASMs during the acute phase, (%) | 10 (50.0%) | 13 (22.4%) | 0.020 | | The number of prescribed ASMs during the acute phase, (%) | 2.5 (2-4) | 2 (1-3) | 0.034 | | Encephalitis-associated symptoms | | | | | Prodromal symptoms, (%) | 12 (60.0%) | 31 (53.4%) | 0.611 | | Altered level of consciousness, (%) | 7 (35.0%) | 16 (27.6%) | 0.531 | | Behavior disorders, (%) | 12 (60.0%) | 24 (41.4%) | 0.150 | | Short-term memory deficits, (%) | 7 (35.0%) | 7 (12.1%) | 0.021 | | Cognitive disorders, (%) | 9 (45.0%) | 18 (31.0%) | 0.258 | | Speech disorders, (%) | 2 (10.0%) | 5 (8.6%) | 0.852 | | Sleep disorders, (%) | 2 (10.0%) | 5 (8.6%) | 0.852 | | Central hypoventilation, (%) | 0 | 3 (5.2%) | 0.300 | | Autonomic dysfunction, (%) | 1 (5.0%) | 3 (5.2%) | 0.976 | | The number of associated symptoms at onset, (%) | 3 (2-3) | 2 (1-3) | 0.037 | | ICU admission, (%) | 9 (45.0%) | 19 (32.5%) | 0.325 | | Lung infection, (%) | 5 (25.0%) | 20 (34.5%) | 0.433 | | Tumors, (%) | 3 (15.0%) | 3 (5.2%) | 0.155 | | Abnormal EEG findings, (%) | 14 (87.5%) | 31 (68.9%) | 0.146 | | Slow activity, (%) | 10 (62.5%) | 20 (44.4%) | 0.215 | | IEDs, (%) | 4 (25.0%) | 11 (24.4%) | 0.965 | | Abnormal MRI findings, (%) | 14 (73.7%) | 34 (58.6%) | 0.240 | | T-plus, (%) | 10 (52.6%) | 28 (48.3%) | 0.742 | | Extra-T, (%) | 2 (10.5%) | 7 (12.1%) | 0.856 | | Both, (%) | 8 (42.1%) | 17 (29.3%) | 0.301 | | Days between initiation of immunotherapy and onset, days, median [IQR] | 9 [7-13] | 11 [5-16] | 0.643 | | MRS scores at onset, median [IQR] | 3 [1-4] | 2.5 [1-4] | 0.460 | | MRS scores at discharge, median [IQR] | 2 [1-3] | 1 [0-3] | 0.067 |
|
|
